A Strong Recovery? PE Life Sciences and Healthcare Investment Opportunities in 2021

01/26/21 • 25 min

How did PE investments in life sciences and healthcare fare in 2020, and what do this year and future years have in store for those sectors? In this episode, Dechert's Robert Darwin and senior PE leaders with experience at Blue Ox Healthcare, Mid Europa Partners, TPG and GHO Capital discuss key themes and opportunities affecting private equity investment in life sciences and healthcare and how the market is shaping up in the U.S. and Europe, in 2021 and beyond.

Previous Episode

SPACs, Election Impact and Industry Resilience: 2021 Global Private Equity Outlook

After a surprising surge in Q3 2020, will private equity buyout activity remain strong in 2021? In this special episode, industry leaders from First Atlantic, H.I.G. Capital and One Equity Partners offer their perspectives on findings from Dechert and Mergemarket’s 2021 Global Private Equity Outlook report as well as the global trends likely to impact dealmaking in the year ahead, including the resilience of the industry in the face of COVID-19, implications of the U.S. election, SPACs as an exit path for PE sponsors, and more.

Next Episode

Sidecar: The Corporate Transparency Act – Will My Business Be Affected?

Committed Capital Sidecar is our new, bite-sized feature which quickly covers a key development affecting the private equity industry.

In this inaugural Sidecar episode, partners from Dechert’s global private equity practice discuss the administrative and compliance burdens that businesses may face with the recent passage of the U.S. Corporate Transparency Act. Aimed at preventing money laundering and the financing of terrorism through shell companies, the Act requires business entities formed or operating within the United States to disclose the identity of their beneficial owners. The discussion also examines international initiatives in this area and the likely evolution of this legislation.